Canton Strategic Holdings, Inc.

CNTN
NASDAQBiotechnology

IPO Price

N/A

Current Price

$3.30

Return

N/A

Market Cap

$187.0M

IPO Date

Jan 12, 2022

Lockup End

Jul 11, 2022

Lockup Status

Lockup expired 1388days ago

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price
IPO Price
Lockup End

Performance Summary

First Day
N/A
1 Month
N/A
3 Months
N/A
6 Months
N/A
1 Year
N/A
Since IPO
N/A

Canton Strategic Holdings, Inc. (CNTN) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

Canton Strategic Holdings, Inc. (ticker: CNTN) specializes in competitive advantages while maintaining strategic capabilities in innovation initiatives, positioning itself within the Biotechnology sector through operational excellence and cost-effective alternatives. The company has developed its operations around innovation focus, creating market differentiation through specialized expertise and subscription-based recurring revenue that supports sustainable growth and customer relationship development. The company completed its public offering on 2022-01-12, accessing capital markets during customer demand shifts within the Biotechnology landscape. The IPO timing reflected the company's strategic positioning and growth trajectory, with market reception emphasizing management's execution capabilities and the company's approach to competitive advantages as key value creation drivers in an evolving competitive environment. Post-IPO trading performance has demonstrated mixed market reception as investors assess business model adaptation and strategic positioning within industry trends. Market assessment focuses on the company's operational excellence and strategic emphasis on innovation initiatives as indicators of long-term competitive positioning within the Biotechnology sector, with investors evaluating operational execution and market opportunity capture relative to industry development trends. The lockup period expires June 28, 2022, providing market insights into management and early investor confidence in strategic direction and competitive positioning. Given the company's focus on competitive advantages and emphasis on innovation focus, insider trading decisions will likely reflect assessments of execution progress, competitive dynamics, and growth opportunity realization within the evolving Biotechnology market landscape.

Performance Overview

Canton Strategic Holdings, Inc. completed its IPO on Jan 12, 2022. Performance data will be updated as trading data becomes available. The company trades on the NASDAQ exchange under the ticker symbol CNTN.

Lockup Expiration

The lockup period for Canton Strategic Holdings, Inc. expired 1388 days ago on Jul 11, 2022. Insiders and early investors are now free to sell their pre-IPO shares. The post-lockup trading period is often volatile as the market absorbs any additional supply from insider selling.

Industry Context

Canton Strategic Holdings, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing CNTN as an investment.

Trading History

Canton Strategic Holdings, Inc. is actively trading in the public markets with a current share price of $3.30. The company went public at N/A per share, representing a decline of 0.0% from the initial offering price. With a current market capitalization of $187.0M, Canton Strategic Holdings, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.

Important Disclaimer

This analysis of Canton Strategic Holdings, Inc. (CNTN) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

3
Pre-Expiry Average
Minimal
78
Expiry Day
Very High
57
Post-Expiry (30d)
High

Activity Heatmap

60 days before/after lockup expiry
Intensity Scale:
Minimal
Low
Moderate
High
Very High
Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Related IPOs

TickerCompanyIndustryIPO DateIPO PriceCurrentReturn
EVMNEvommune, Inc.BiotechnologyNov 6, 2025$16.00$25.58+59.9%
MPLTMapLight Therapeutics, Inc.BiotechnologyOct 27, 2025$17.00$30.31+78.3%
LBRXLB Pharmaceuticals IncBiotechnologySep 11, 2025$15.00$31.38+109.2%
CURXCuranex Pharmaceuticals IncBiotechnologyAug 26, 2025$4.00$0.43-89.3%
CAICaris Life Sciences, Inc.BiotechnologyJun 18, 2025$21.00$18.44-12.2%
MENSJyong Biotech Ltd.BiotechnologyJun 17, 2025N/A$2.17N/A
AARDAardvark Therapeutics, Inc.BiotechnologyFeb 13, 2025$16.00$5.59-65.1%
SIONSionna Therapeutics, Inc.BiotechnologyFeb 7, 2025$18.00$39.59+119.9%

Related IPO Analysis

KO
By • Founder & Data Analyst